Hormone Replacement Therapy in Females Can Decrease the Risk of Lung Cancer: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Yao, Yanwen ^a   Gu, Xiaoling ^a   Zhu, Juehua ^a   Yuan, Dongmei ^a   Song, Yong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY MASS; CANCER RISK; CORRELATION ANALYSIS; EGGER TEST; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; MENOPAUSE; META ANALYSIS; SMOKING; STATISTICAL ANALYSIS;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LUNG NEOPLASMS; RISK;

EID: 84881495984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071236     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
3. Biglia N, Gadducci A, Ponzone R, Roagna R, Sismondi P, (2004) Hormone replacement therapy in cancer survivors. Maturitas 48: 333-346.
4. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L, (1989) Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44: 833-839.
5. Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, et al. (2010) Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 102: 1413-1421.
6. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, et al. (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374: 1243-1251.
7. Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, et al. (2007) Hormone replacement therapy and lung cancer risk in Chinese. Cancer 110: 1768-1775.
8. Clague J, Reynolds P, Sullivan-Halley J, Ma H, Lacey JV Jr, et al. (2011) Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. Cancer Epidemiol Biomarkers Prev 20: 560-564.
9. Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, et al. (2007) Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology 73: 305-310.
10. Chene G, Thompson SG, (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144: 610-621.
11. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
12. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
13. Blackman JA, Coogan PF, Rosenberg L, Strom BL, Zauber AG, et al. (2002) Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11: 561-567.
14. Elliott AM, Hannaford PC, (2006) Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 73: 331-335.
15. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 58-66.
16. Kabat GC, Miller AB, Rohan TE, (2007) Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 120: 2214-2220.
17. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE, (2003) Hormonal factors and risk of lung cancer among women? Int J Epidemiol 32: 263-271.
18. Liu Y, Inoue M, Sobue T, Tsugane S, (2005) Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 117: 662-666.
19. Mahabir S, Spitz MR, Barrera SL, Dong YQ, Eastham C, et al. (2008) Dietary boron and hormone replacement therapy as risk factors for lung cancer in women. Am J Epidemiol 167: 1070-1080.
20. Olsson H, Bladstrom A, Ingvar C, (2003) Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 102: 565-570.
21. Persson I, Yuen J, Bergkvist L, Schairer C, (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67: 327-332.
22. Pukkala E, Tulenheimo-Silfvast A, Leminen A, (2001) Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 12: 111-115.
23. Rodriguez C, Spencer Feigelson H, Deka A, Patel AV, Jacobs EJ, et al. (2008) Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 17: 655-660.
24. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
25. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR, (2004) Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10: 113-123.
26. Slatore CG, Chien JW, Au DH, Satia JA, White E, (2010) Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 28: 1540-1546.
27. Smith JR, Barrett-Connor E, Kritz-Silverstein D, Wingard DL, Al-Delaimy WK, (2009) Hormone use and lung cancer incidence: the Rancho Bernardo cohort study. Menopause 16: 1044-1048.
28. Taioli E, Wynder EL, (1994) Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86: 869-870.
29. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE, (1988) Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 48: 7279-7284.
30. Brinton LA, Schwartz L, Spitz MR, Park Y, Hollenbeck AR, et al. (2012) Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Causes Control 23: 487-496.
31. Meinhold CL, Berrington de Gonzalez A, Bowman ED, Brenner AV, Jones RT, et al. (2011) Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. Int J Cancer 128: 1404-1413.
32. Zhang Y, He J, Deng Y, Zhang J, Li X, et al. (2011) The insertion/deletion (I/D) polymorphism in the Angiotensin-converting enzyme gene and cancer risk: a meta-analysis. BMC Med Genet 12: 159.
33. Gompel A, Santen RJ, (2012) Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 15: 241-249.
34. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG, (2010) Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 19: 3119-3130.
35. Freedman DM, Rajaraman P, Fuhrman B, Hoffbeck R, Alexander BH, (2010) Sunlight, hormone replacement status and colorectal cancer risk in postmenopausal women. Int J Cancer 126: 1997-2001.
36. Hodis HN, Mack WJ, (2009) Coronary heart disease and hormone replacement therapy after the menopause. Climacteric 12Suppl 1: 71-75.
37. Low AK, Russell LD, Holman HE, Shepherd JM, Hicks GS, et al. (2002) Hormone replacement therapy and coronary heart disease in women: a review of the evidence. Am J Med Sci 324: 180-184.
38. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A, (2006) Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24: 59-63.
39. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, et al. (2001) Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285: 340-347.
40. Siegfried JM, (2006) Hormone replacement therapy and decreased lung cancer survival. J Clin Oncol 24: 9-10.
41. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, et al. (2005) Progesterone receptor in non-small cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65: 6450-6458.
42. Moore KA, Mery CM, Jaklitsch MT, Estocin AP, Bueno R, et al. (2003) Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg 76: 1789-1795.
43. Thomas L, Doyle LA, Edelman MJ, (2005) Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 128: 370-381.
44. Vandenbroucke JP, (2009) The HRT controversy: observational studies and RCTs fall in line. Lancet 373: 1233-1235.
45. Prentice RL (2008) Data analysis methods and the reliability of analytic epidemiologic research. Epidemiology 19: 785-788; discussion 789-793.
46. Vandenbroucke JP, (2004) When are observational studies as credible as randomised trials? Lancet 363: 1728-1731.
47. Vandenbroucke JP, Psaty BM, (2008) Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300: 2417-2419.
48. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, et al. (2013) 50-year trends in smoking-related mortality in the United States. N Engl J Med 368: 351-364.